A Study Comparing 4 Doses Of GW810781 Versus Placebo In HIV-Infected Patients
NCT ID: NCT00046332
Last Updated: 2013-02-21
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
100 participants
INTERVENTIONAL
2002-06-30
2003-01-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Phase IIa Dose-ranging Study of GSK1349572 in HIV-1 Infected Adults
NCT00708110
A Study of AMD11070 in HIV-infected Patients Carrying X4-tropic Virus
NCT00361101
Treatment of AIDS and AIDS Related Complex. Part-1- Treatment of Patients With ARC (AZT Vs. Placebo)
NCT00002063
Pilot Study to Evaluate the Efficacy of Zidovudine in Preventing CD4+ Lymphocyte Decline in Patients With Primary HIV Infection. (One Treatment Arm Receives Placebo)
NCT00000765
Safety and Tolerability of Z-100 in Patients With Early HIV Infection
NCT00016692
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
GW810781
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* HIV infection with viral load \>400-50,000 copies/mL.
* CD4 cell count \>50 cells/mm.
Exclusion Criteria
* Abnormal ECG or other chronic health conditions as noted on screening physical exam.
* Previous participation in an experimental drug trial(s) within 30 days of the screening visit for this study.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Shionogi
INDUSTRY
GlaxoSmithKline
INDUSTRY
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
GSK Clinical Trial, MD,MPH
Role: STUDY_DIRECTOR
GlaxoSmithKline
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
GSK Clinical Trials Call Center
Phoenix, Arizona, United States
GSK Clinical Trials Call Center
Los Angeles, California, United States
GSK Clinical Trials Call Center
San Diego, California, United States
GSK Clinical Trials Call Center
San Francisco, California, United States
GSK Clinical Trials Call Center
West Hollywood, California, United States
GSK Clinical Trials Call Center
Denver, Colorado, United States
GSK Clinical Trials Call Center
Washington D.C., District of Columbia, United States
GSK Clinical Trials Call Center
Altamonte Springs, Florida, United States
GSK Clinical Trials Call Center
Fort Lauderdale, Florida, United States
GSK Clinical Trials Call Center
Miami, Florida, United States
GSK Clinical Trials Call Center
Tampa, Florida, United States
GSK Clinical Trials Call Center
Atlanta, Georgia, United States
GSK Clinical Trials Call Center
Indianapolis, Indiana, United States
GSK Clinical Trials Call Center
Minneapolis, Minnesota, United States
GSK Clinical Trials Call Center
New York, New York, United States
GSK Clinical Trials Call Center
New York, New York, United States
GSK Clinical Trials Call Center
New York, New York, United States
GSK Clinical Trials Call Center
The Bronx, New York, United States
GSK Clinical Trials Call Center
Chapel Hill, North Carolina, United States
GSK Clinical Trials Call Center
Charlotte, North Carolina, United States
GSK Clinical Trials Call Center
Durham, North Carolina, United States
GSK Clinical Trials Call Center
Dallas, Texas, United States
GSK Clinical Trials Call Center
Houston, Texas, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ITG20001
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.